Lundbeck Establishes Shanghai Research Center To Find More Chinese Partnerships
This article was originally published in PharmAsia News
Executive Summary
Danish pharma Lundbeck A/S announced Oct. 14 that it established a research center in Shanghai to increase its footprint in the largest emerging market and better position itself for more partnerships in China
You may also be interested in...
Lundbeck Unveils Depression Education Program In China
Healthcare experts estimate a large share of China’s depression population has never been diagnosed thanks to low recognition of the disease, creating a potentially huge population of patients who could benefit from treatment.
Lundbeck Steps Up Chinese Operations; Revises Lexapro Terms With J&J
Danish drug maker Lundbeck is increasing its sales force in China and revising its licensing agreement with partner Xian-Janssen - Johnson & Johnson's China subsidiary - to co-market its top-selling antidepressant Lexapro (escitalopram) in China
Lilly Shifts Gears In China With New Shanghai-based R&D Center
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes